Shanetta D Ore

Array ( [id] => 13778057 [patent_doc_number] => 20190002567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => NEW USE OF AN ANTI-CD303 TRANSMEMBRANE PROTEIN ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/062284 [patent_app_country] => US [patent_app_date] => 2016-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16062284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17921618 [patent_doc_number] => 11464839 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Methods and vaccines for inducing immune responses to multiple different MHC molecules [patent_app_type] => utility [patent_app_number] => 15/781393 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 7577 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662577 [patent_doc_number] => 20170151282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'COMPOSITIONS AND METHODS FOR SELECTIVE PHAGOCYTOSIS OF HUMAN CANCER CELLS' [patent_app_type] => utility [patent_app_number] => 15/366844 [patent_app_country] => US [patent_app_date] => 2016-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 88 [patent_no_of_words] => 37975 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15366844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704652 [patent_doc_number] => 20170173151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74' [patent_app_type] => utility [patent_app_number] => 15/366791 [patent_app_country] => US [patent_app_date] => 2016-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 38408 [patent_no_of_claims] => 69 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15366791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590885 [patent_doc_number] => 20180346991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => HEATR1 AS A MARKER FOR CHEMORESISTANCE [patent_app_type] => utility [patent_app_number] => 15/780074 [patent_app_country] => US [patent_app_date] => 2016-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15780074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185361 [patent_doc_number] => 20190112385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => ANTI-MESOTHELIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/768231 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11922705 [patent_doc_number] => 09790275 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Compositions and methods to enhance the immune system' [patent_app_type] => utility [patent_app_number] => 15/338198 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5485 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15338198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604120 [patent_doc_number] => 20170121421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST' [patent_app_type] => utility [patent_app_number] => 15/333285 [patent_app_country] => US [patent_app_date] => 2016-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 81632 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15333285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588481 [patent_doc_number] => 20170112891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'HINDERED DISULFIDE DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/293743 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 64167 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15293743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393363 [patent_doc_number] => 11242365 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => FOXM1-derived peptide, and vaccine including same [patent_app_type] => utility [patent_app_number] => 15/762436 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 8 [patent_no_of_words] => 34555 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 320 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18273722 [patent_doc_number] => 11612643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Col14A1-derived tumor antigen polypeptide and use thereof [patent_app_type] => utility [patent_app_number] => 16/338201 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7761 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850301 [patent_doc_number] => 20170224793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'TUMOR IMMUNITY' [patent_app_type] => utility [patent_app_number] => 15/275771 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 21665 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15275771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14870789 [patent_doc_number] => 20190285636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) [patent_app_type] => utility [patent_app_number] => 15/762076 [patent_app_country] => US [patent_app_date] => 2016-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364108 [patent_doc_number] => 20170002088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES' [patent_app_type] => utility [patent_app_number] => 15/269027 [patent_app_country] => US [patent_app_date] => 2016-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 77099 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15269027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364095 [patent_doc_number] => 20170002076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/268389 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 44307 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15268389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837215 [patent_doc_number] => 20190022092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist [patent_app_type] => utility [patent_app_number] => 15/760370 [patent_app_country] => US [patent_app_date] => 2016-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 132571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15760370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13672765 [patent_doc_number] => 20160375116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => METHOD FOR TREATING STAGE IV MELANOMA [patent_app_type] => utility [patent_app_number] => 15/263039 [patent_app_country] => US [patent_app_date] => 2016-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15263039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867675 [patent_doc_number] => 20190030178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/758520 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15758520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938435 [patent_doc_number] => 11472876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Conditionally active polypeptides [patent_app_type] => utility [patent_app_number] => 15/773122 [patent_app_country] => US [patent_app_date] => 2016-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 49307 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 380 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11569859 [patent_doc_number] => 20170108504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'TREATING BAX(DELTA)2-POSITIVE CANCER WITH CHEMOTHERAPIES TARGETING CASPASE 8' [patent_app_type] => utility [patent_app_number] => 15/245966 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 12399 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15245966 [rel_patent_id] =>[rel_patent_doc_number] =>)